Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Ball

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
The Lancet. Rheumatology|August 11, 2022
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trialJagdeep Nanchahal, Catherine Ball, Ines Rombach, et al.
Genetics|November 8, 2018
Estimates of the Heritability of Human Longevity Are Substantially Inflated due to Assortative MatingJ Graham Ruby, Kevin M Wright, Kristin A Rand, et al.
Environmental Health Perspectives|September 4, 2004
Standards for microarray data: an open letterCatherine Ball, Alvis Brazma, Helen Causton, et al.
Bioorganic & Medicinal Chemistry Letters|November 6, 2010
The identification of novel orally active mGluR5 antagonist GSK2210875Maria Pilla, Michela Andreoli, Michela Tessari, et al.
Ebiomedicine|July 10, 2018
Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical TrialJagdeep Nanchahal, Catherine Ball, Dominique Davidson, et al.
Nature Biotechnology|January 13, 2006
Wrestling with SUMO and bio-ontologiesChristian Stoeckert, Catherine Ball, Alvis Brazma, et al.
Genome Biology|September 13, 2002
Design and implementation of microarray gene expression markup language (MAGE-ML)Paul T Spellman, Michael Miller, Jason Stewart, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
The Lancet. Rheumatology|August 11, 2022
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trialJagdeep Nanchahal, Catherine Ball, Ines Rombach, et al.
Genetics|November 8, 2018
Estimates of the Heritability of Human Longevity Are Substantially Inflated due to Assortative MatingJ Graham Ruby, Kevin M Wright, Kristin A Rand, et al.
Environmental Health Perspectives|September 4, 2004
Standards for microarray data: an open letterCatherine Ball, Alvis Brazma, Helen Causton, et al.
Bioorganic & Medicinal Chemistry Letters|November 6, 2010
The identification of novel orally active mGluR5 antagonist GSK2210875Maria Pilla, Michela Andreoli, Michela Tessari, et al.
Ebiomedicine|July 10, 2018
Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical TrialJagdeep Nanchahal, Catherine Ball, Dominique Davidson, et al.
Nature Biotechnology|January 13, 2006
Wrestling with SUMO and bio-ontologiesChristian Stoeckert, Catherine Ball, Alvis Brazma, et al.
Genome Biology|September 13, 2002
Design and implementation of microarray gene expression markup language (MAGE-ML)Paul T Spellman, Michael Miller, Jason Stewart, et al.
Pageof 2